Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant

Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant

Copyright © 2013 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 149(2013), 1 vom: 01. Okt., Seite 11-24
1. Verfasser: Yu, Yun-Zhou (VerfasserIn)
Weitere Verfasser: Wang, Shuang, Bai, Jie-Ying, Zhao, Meng, Chen, Ao, Wang, Wen-Bin, Chang, Qing, Liu, Si, Qiu, Wei-Yi, Pang, Xiao-Bin, Xu, Qing, Sun, Zhi-Wei
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Alzheimer's disease Carrier protein DNA vaccine Immunotherapy Toxin fragment Alzheimer Vaccines Amyloid beta-Peptides Epitopes mehr... Immunoglobulin G Malaria Vaccines PADRE 45 Peptide Fragments Vaccines, DNA amyloid beta-protein (1-15) amyloid beta-protein (1-42) Interleukin-4 207137-56-2 Interferon-gamma 82115-62-6
LEADER 01000naa a22002652 4500
001 NLM229464319
003 DE-627
005 20231224082221.0
007 cr uuu---uuuuu
008 231224s2013 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2013.05.016  |2 doi 
028 5 2 |a pubmed24n0765.xml 
035 |a (DE-627)NLM229464319 
035 |a (NLM)23886550 
035 |a (PII)S1521-6616(13)00158-7 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Yu, Yun-Zhou  |e verfasserin  |4 aut 
245 1 0 |a Effective DNA epitope chimeric vaccines for Alzheimer's disease using a toxin-derived carrier protein as a molecular adjuvant 
264 1 |c 2013 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 12.11.2013 
500 |a Date Revised 17.09.2013 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2013 Elsevier Inc. All rights reserved. 
520 |a Active amyloid-beta (Aβ) immunotherapy is under investigation to prevent or treat Alzheimer disease (AD). We describe here the immunological characterization and protective effect of DNA epitope chimeric vaccines using 6 copies of Aβ1-15 fused with PADRE or toxin-derived carriers. These naked 6Aβ15-T-Hc chimeric DNA vaccines were demonstrated to induce robust anti-Aβ antibodies that could recognize Aβ oligomers and inhibit Aβ oligomer-mediated neurotoxicity, result in the reduction of cerebral Aβ load and Aβ oligomers, and improve cognitive function in AD mice, but did not stimulate Aβ-specific T cell responses. Notably, toxin-derived carriers as molecular adjuvants were able to substantially promote immune responses, overcome Aβ-associated hypo-responsiveness, and elicit long-term Aβ-specific antibody response in 6Aβ15-T-Hc-immunized AD mice. These findings suggest that our 6Aβ15-T-Hc DNA chimeric vaccines can be used as a safe and effective strategy for AD immunotherapy, and toxin-derived carrier proteins are effective molecular adjuvants of DNA epitope vaccines for Alzheimer's disease 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Alzheimer's disease 
650 4 |a Carrier protein 
650 4 |a DNA vaccine 
650 4 |a Immunotherapy 
650 4 |a Toxin fragment 
650 7 |a Alzheimer Vaccines  |2 NLM 
650 7 |a Amyloid beta-Peptides  |2 NLM 
650 7 |a Epitopes  |2 NLM 
650 7 |a Immunoglobulin G  |2 NLM 
650 7 |a Malaria Vaccines  |2 NLM 
650 7 |a PADRE 45  |2 NLM 
650 7 |a Peptide Fragments  |2 NLM 
650 7 |a Vaccines, DNA  |2 NLM 
650 7 |a amyloid beta-protein (1-15)  |2 NLM 
650 7 |a amyloid beta-protein (1-42)  |2 NLM 
650 7 |a Interleukin-4  |2 NLM 
650 7 |a 207137-56-2  |2 NLM 
650 7 |a Interferon-gamma  |2 NLM 
650 7 |a 82115-62-6  |2 NLM 
700 1 |a Wang, Shuang  |e verfasserin  |4 aut 
700 1 |a Bai, Jie-Ying  |e verfasserin  |4 aut 
700 1 |a Zhao, Meng  |e verfasserin  |4 aut 
700 1 |a Chen, Ao  |e verfasserin  |4 aut 
700 1 |a Wang, Wen-Bin  |e verfasserin  |4 aut 
700 1 |a Chang, Qing  |e verfasserin  |4 aut 
700 1 |a Liu, Si  |e verfasserin  |4 aut 
700 1 |a Qiu, Wei-Yi  |e verfasserin  |4 aut 
700 1 |a Pang, Xiao-Bin  |e verfasserin  |4 aut 
700 1 |a Xu, Qing  |e verfasserin  |4 aut 
700 1 |a Sun, Zhi-Wei  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 149(2013), 1 vom: 01. Okt., Seite 11-24  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:149  |g year:2013  |g number:1  |g day:01  |g month:10  |g pages:11-24 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2013.05.016  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 149  |j 2013  |e 1  |b 01  |c 10  |h 11-24